The radiopharmaceutical is already approved for use in PET imaging in men with suspected prostate cancer recurrence.
Blue Earth Diagnostics has completed patient enrollment in its phase 3 REVELATE clinical trial (NCT04410133), which is evaluating the diagnostic performance of 18F-fluciclovine PET (Axumin, Blue Earth Diagnostics) for detecting recurrent brain metastases.
The prospective, multicenter, single-arm study has a target enrollment of 150 adult participants with a history of brain metastases who have undergone prior radiation therapy of those lesions.
Delivered via intravenous bolus, 18F-fluciclovine PET helps visualize the increased amino transport associated with malignancies and consists of a synthetic amino acid that is labeled with radioisotope 18F for PET imaging.
The primary end point of the REVELATE trial is the assessment of the Negative Percent Agreement (NPA, equivalent to specificity) and Positive Percent Agreement (PPA, equivalent to sensitivity) of 18F-fluciclovine PET in detecting recurrent brain metastases on a patient level. In addition, secondary end points will evaluate Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 18F-fluciclovine PET for detecting recurrent brain metastases.
"Recommendations from the Response Assessment in Neuro-Oncology/PET working group in 2019 cite the potential utility of amino acid PET radiopharmaceuticals in distinguishing brain tissue changes after radiation therapy from recurrent brain metastases," said Eugene J. Teoh, MBBS, MRCP, FRCR, DPhil, chief medical officer of Blue Earth Diagnostics, in a statement. "In noting that existing data have been derived mainly from single center, retrospective studies, a call for prospective multi-center studies has been re-iterated to validate these observations."
In addition to REVELATE, Blue Earth has also launched the phase 2b PURSUE clinical trial (NCT04410367) to help establish image interpretation criteria for 18F-fluciclovine PET in recurrent brain metastases. The study will evaluate the sensitivity and specificity of different thresholds of the tracer's uptake on visual reads.
18F-fluciclovine PET was originally FDA-approved on May 27, 2016 for use in patients with recurrent prostate cancer.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.